COVID GEAS: COVID-19 National Survey in Patients With Systemic Autoimmune Diseases
| Autor: | del Carmelo Gracia Tello, Borja, Sáez-Comet, Luis, Pallarés, Lucio, Velilla, José, Marín Ballvé, Adela, Martinez-Lostao, Luis, Simeón Aznar, Carmen Pilar, Fanlo, Patricia |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [del Carmelo Gracia B, Marín A] Sytemic Autoimmune Diseases Unit, Internal Medicine Department, Lozano Blesa University Clinical Hospital, Zaragoza, Spain. [Sáez L, Velilla J] Sytemic Autoimmune Diseases Unit, Internal Medicine Department, Miguel Servet University Clinical Hospital, Zaragoza, Spain. [Pallarés L] Sytemic Autoimmune Diseases Unit, Internal Medicine Department, Son Espases University Clinical Hospital, Palma de Mallorca, Spain. [Martinez-Lostao L] Immunology Department, Lozano Blesa University Hospital, Zaragoza, Spain. [Simeón CP] Unitat de Malalties Autoimmunes Sistèmiques, Servei de Medicina Interna, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Fanlo P] Systemic Autoimmune Diseases Unit, Internal Medicine Department, Universitary Complex of Navarra, Pamplona, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Medicine (General)
SARS-CoV-2 Immune System Diseases::Autoimmune Diseases [DISEASES] enfermedades del sistema inmune::enfermedades autoinmunes [ENFERMEDADES] COVID-19 COVID-19 infection anti-TNF survey systemic erythematosus lupus systemic autoimmune disease corticosteroids Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] General Medicine Other subheadings::Other subheadings::/drug therapy [Other subheadings] COVID-19 (Malaltia) Enquestes Malalties autoimmunitàries - Tractament R5-920 |
| Zdroj: | Frontiers in medicine, 8:808608 Frontiers in Medicine, Vol 8 (2022) Scientia |
| Popis: | ObjectivesCOVID-19 outcomes in population with systemic autoimmune diseases (SAD) remain poorly understood. The aim was to examine demographic and clinical factors associated with COVID-19 infection in people with rheumatic disease.MethodsTwo phases cross-sectional survey of individuals with rheumatic disease in April 2020 and October 2020. COVID infection, severity of disease, age, sex, smoking status, underlying rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analyzed.ResultsA total of 1,529 individuals with autoimmunity disease diagnosis were included. Out of 50 positive patients, 21 required telephone medical assistance, 16 received assessment by primary care physician, 9 were evaluated in Emergency Department and 4 patient required hospitalization. Multivariate analysis was performed without obtaining differences in any of the systemic autoimmune diseases. Regarding the treatments, significant differences were found (p 0.011) in the treatment with anti-TNF-alpha agents with OR 3.422 (1.322–8.858) and a trend to significance (p 0.094) was observed in patients receiving mycophenolate treatment [OR 2.016 (0.996–4-081)].ConclusionsAnti-TNF-alpha treatment was associated with more than 3-fold risk of suffering from SARS-CoV-2 infection, although in all cases infection was mild. Cumulative incidence in patients with SAD was up to 5 times higher than general population but with great differences between autoimmune diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|